TheranosticTrials.org

Clinical Trial · NCT07589101

5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors

Overview

This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors. The 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread. In this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET/CT imaging using 68Ga-MY. The imaging results will be compared with 18F-FDG. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-MY PET/CT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.

Sponsor

Peking University Cancer Hospital & Institute

Phase

N/A

Contacts

Hua Zhu (CONTACT)

zhuhuabch@pku.edu.cn

010-88196495

Hua Zhu (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT07589101

Drug / Compound

68Ga-MY

Isotope(s):
Target(s):
  • 5T4
  • Trop-2

Eligibility

Inclusion

  • Expected survival ≥12 weeks.
  • 1. Patients with solid tumors;
  • Presence of measurable lesions on imaging examinations;

Exclusion

  • Diagnosis of claustrophobia or other psychiatric disorders;
  • Unable to remain in supine position for 30 minutes;
  • Women who are planning pregnancy, pregnant, or breastfeeding;
  • Refusal to participate in this clinical study;
  • 1. Severe hepatic or renal dysfunction;